Post-acute infection syndrome

From WikiProjectMed
(Redirected from Post-viral syndrome)
Jump to navigation Jump to search
Post-acute infection syndrome

Post-acute infection syndromes (PAISs) or post-infectious syndromes are medical conditions characterized by symptoms attributed to a prior infection. While it is commonly assumed that people either recover or die from infections, long-term symptoms—or sequelae—are a possible outcome as well.[1] Examples include long COVID (post-acute sequelae of SARS-CoV-2 infection, PASC), chronic fatigue syndrome (ME/CFS), and post-Ebola virus syndrome.[1] Common symptoms include post-exertional malaise (PEM), severe fatigue, neurocognitive symptoms, flu-like symptoms, and pain. The pathology of most of these conditions is not understood and management is generally symptomatic.

Symptoms and signs

Chart showing symptoms of long COVID

PAIS symptoms are often non-specific and similar despite diverse prior infections. Symptoms commonly included in definitions of PAIS include post-exertional malaise, severe fatigue, neurocognitive and sensory symptoms, flu-like symptoms, unrefreshing sleep, muscle pain, and joint pain. Symptoms can vary among affected people.[1] Some PAIS symptoms are more specific. For example, eye problems are common in post-Ebola virus syndrome, and profound weakness is seen in post-polio syndrome and post-West Nile fevers.[1]

Symptoms can be severe and debilitating, resulting in lowered quality of life or inability to work.[1] The onset of symptoms may be delayed, often by decades in the case of post-polio syndrome, and their severity may fluctuate over time.[2]

Causes

Microscope slide of cells infected with EBV
Cells infected with Epstein–Barr virus, one of the viruses implicated in PAISs

Pathogens associated with PAISs include SARS-CoV-2 (causing COVID-19), Ebolavirus, Dengue virus, poliovirus, SARS-CoV-1 (causing SARS), Chikungunya virus, Epstein–Barr virus (EBV), West Nile virus (WNV), Ross River virus (RRV), Coxsackie B, influenza A virus subtype H1N1, varicella zoster virus (VZV), Coxiella burnetii, Borrelia, and Giardia. However, the strength of evidence associating these pathogens with chronic illness varies.[1]

The pathophysiology of most PAISs is poorly understood, but the overlap in symptoms despite disparate infectious triggers implies a possible shared pathology. For most conditions, no chronic infection has been detected.[1]

Mechanism

The pathology of post-acute infections syndromes is not understood. The commonality in symptoms between illnesses may point to a common pathology.[1] Major hypotheses include persistence of the original pathogen or its remnants, autoimmunity, chronic inflammation, reactivation of other latent infections, microbiome dysbiosis, or damage to organs, which may include the lungs, brain, kidneys, heart, or blood vessels.[1][3]

Diagnosis

ME/CFS has many competing definitions.

In the absence of tests for most PAISes, diagnosis is usually based on the patient's history, symptoms, and eliminating other potential causes. Available tests often fail to explain patients' symptoms, but this does not suggest they are not real. The complexity of diagnosing PAISes may lead to long delays in diagnosis.[2]

Diagnostic criteria vary among illnesses, and have at times been the subject of intense debate.[1] For example, several definitions of ME/CFS have been in use.[1]

Classification

PAIS is a broad term describing conditions attributed to various infections, including long COVID, ME/CFS, post-Ebola virus syndrome, post-dengue fatigue syndrome, post-polio syndrome, post-SARS syndrome, post-chikungunya disease, Q fever fatigue syndrome, post-treatment Lyme disease syndrome, and symptoms observed after other infections lacking a specific name.[1][3] Other known sequelae of infections include multisystem inflammatory syndrome in children (MIS-C), and subacute sclerosing panencephalitis (a deadly consequence of measles that can be delayed by years).[1]

Management

Treatment options for most PAISes are limited. In general, the focus is on managing symptoms,[3] and management strategies for ME/CFS may benefit patients with similar symptoms.[2]

Prognosis

Some people with PAISs recover over a period ranging from weeks to years while others remain ill.[2][1] Many studies have shown that symptoms can continue for at least several years until the studies' conclusion. Studies of PTLDS ran longer and found increased rates of symptoms for up to 27 years.[1] In the case of ME/CFS prognosis is poor and the illness is lifelong for most.[4][5]

Epidemiology

Data on epidemiology is limited by the lack of large, rigorous studies; and rates vary by infection. Mononucleosis is among the best studied, and available studies found that 7-9% had persistent symptoms 12 months after infection, and 4% had serious symptoms after 2 years. The British Office of National Statistics data on long COVID say that about 10% of people who had COVID-19 self-reported long COVID 6 months after infection, and about 7% reported long COVID with activity limitations. An Australian study of EBV, C. burnetii, and Ross River Virus found that 11% of participants met the criteria for ME/CFS at 6 months. Around 10-20% of people with SARS also experienced long-term effects.[1]

History

While PAISs were described prior to the COVID-19 pandemic, the emergence of long COVID brought them increased attention.[1]

Society and culture

PAISs cause a significant disease burden, but have received relatively little attention from scientists, potentially delaying the discovery of causes, diagnostic tests, and treatments.[1][6] Infectious disease surveillance programs track acute illness but rarely track the health effects of PAISes.[7] Many doctors are also unfamiliar with them, and may fail to take symptoms seriously.[8][3]

Research

PAISs may have a common cause, and different hypotheses are being studied.[3] Long COVID has increased the overall pace of research.[3] Yale School of Medicine operates a research center, founded in 2023, that focuses on PAISs called the Center for Infection & Immunity.[9]

See also

References

  1. ^ a b c d e f g h i j k l m n o p q r Choutka J, Jansari V, Hornig M, Iwasaki A (May 2022). "Unexplained post-acute infection syndromes". Nature Medicine. 28 (5): 911–923. doi:10.1038/s41591-022-01810-6. PMID 35585196.
  2. ^ a b c d "Chronic Symptoms Following Infections". www.cdc.gov. 2023-11-09. Retrieved 2023-12-11.
  3. ^ a b c d e f Owens B (September 2022). "How "long covid" is shedding light on postviral syndromes". BMJ. 378: o2188. doi:10.1136/bmj.o2188. PMID 36130797.
  4. ^ Davis HE, McCorkell L, Vogel JM, Topol EJ (March 2023). "Long COVID: major findings, mechanisms and recommendations". Nature Reviews. Microbiology. 21 (3): 133–146. doi:10.1038/s41579-022-00846-2. PMC 9839201. PMID 36639608.
  5. ^ Ghali A, Lacout C, Fortrat JO, Depres K, Ghali M, Lavigne C (October 2022). "Factors Influencing the Prognosis of Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Diagnostics. 12 (10): 2540. doi:10.3390/diagnostics12102540. PMC 9600584. PMID 36292229.
  6. ^ The Lancet Regional Health – Europe (November 2022). "Long COVID: An opportunity to focus on post-acute infection syndromes". The Lancet Regional Health. Europe. 22: 100540. doi:10.1016/j.lanepe.2022.100540. PMC 9823272. PMID 36624784.
  7. ^ Al-Aly Z, Topol E (February 2024). "Solving the puzzle of Long Covid". Science. 383 (6685): 830–832. Bibcode:2024Sci...383..830A. doi:10.1126/science.adl0867. PMID 38386747.
  8. ^ Steenblock C, Walther R, Tselmin S, Jarzebska N, Voit-Bak K, Toepfner N, et al. (November 2022). "Post COVID and Apheresis - Where are we Standing?". Hormone and Metabolic Research = Hormon- und Stoffwechselforschung = Hormones et Metabolisme. 54 (11): 715–720. doi:10.1055/a-1945-9694. PMID 36113501.
  9. ^ Backman I. "Post-Acute Infection Syndromes Will Be the Focus of New YSM Center". medicine.yale.edu. Retrieved 2023-09-22.
Retrieved from "https://mdwiki.org/wiki/Post-acute_infection_syndrome"